|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM232469679 |
| 003 |
DE-627 |
| 005 |
20240318232842.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.08.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1334.xml
|
| 035 |
|
|
|a (DE-627)NLM232469679
|
| 035 |
|
|
|a (NLM)24211847
|
| 035 |
|
|
|a (PII)S1521-6616(13)00220-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Horwitz, David A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.12.2013
|
| 500 |
|
|
|a Date Revised 18.03.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2013.
|
| 520 |
|
|
|a We report that polyclonal CD8regs generated in one week ex-vivo with anti-CD3/28 beads and cytokines rapidly developed suppressive activity in vitro sustained by TGF-β. In immunodeficient mice, these CD8regs demonstrated a markedly protective, IL-10 dependent activity against a xeno-GVHD. They expressed IL-2Rα/β, Foxp3, TNFR2, and the negative co-stimulatory receptors CTLA-4, PD-1, PD-L1 and Tim-3. Suppressive activity in vitro correlated better with TNFR2 and PD-L1 than Foxp3. Blocking studies suggested that TNF enhanced PD-L1 expression and the suppressive activity of the CD8regs generated. Unlike other polyclonal CD4 and CD8 Tregs, these CD8regs preferentially targeted allogeneic T cells, but they lacked cytotoxic activity against them even after sensitization. Unlike CD4regs, these CD8regs could produce IL-2 and proliferate while inhibiting target cells. If these CD8regs can persist in foreign hosts without impairing immune surveillance, they could serve as a practical remission-inducing product for the treatment of autoimmune diseases, graft-versus-host disease, and allograft rejection
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Cell-based immunotherapy
|
| 650 |
|
4 |
|a IL-2
|
| 650 |
|
4 |
|a PDL1
|
| 650 |
|
4 |
|a Polyclonal CD8+ regulatory T cells
|
| 650 |
|
4 |
|a TGF-beta
|
| 650 |
|
4 |
|a TNFR2
|
| 650 |
|
7 |
|a Antibodies
|2 NLM
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD274 protein, human
|2 NLM
|
| 650 |
|
7 |
|a CTLA-4 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Ctla4 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a FOXP3 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
| 650 |
|
7 |
|a Havcr2 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Hepatitis A Virus Cellular Receptor 2
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-2 Receptor alpha Subunit
|2 NLM
|
| 650 |
|
7 |
|a Pdcd1 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Programmed Cell Death 1 Receptor
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Tumor Necrosis Factor, Type II
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Virus
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 700 |
1 |
|
|a Pan, Stephanie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ou, Jing-Ni
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Julie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Maogen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gray, J Dixon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zheng, Song Guo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 149(2013), 3 vom: 08. Dez., Seite 450-63
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:149
|g year:2013
|g number:3
|g day:08
|g month:12
|g pages:450-63
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.08.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 149
|j 2013
|e 3
|b 08
|c 12
|h 450-63
|